SCHEMBL10323326

SCHEMBL10323326

CC(C)[C@@H]1CCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL943444 1.00
SCHEMBL12384257 1.00
SCHEMBL15624974 0.97 SLC6A3 (0.37)
SCHEMBL10030794 0.92
SCHEMBL482624 0.92
SCHEMBL12119805 0.92
SCHEMBL24351608 0.84 SLC6A3 (0.38)
SCHEMBL22414058 0.84 SLC6A3 (0.38)
SCHEMBL777224 0.83
SCHEMBL801070 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129881-A1 COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING WAVEBREAK THERAPEUTICS LIMITED (US) 2024-06-20 WO disclosed
WO-2024025896-A2 PROTEIN KINASE C (PKC) THETA INHIBITOR COMPOUNDS EVOMMUNE, INC. (US) 2024-02-01 WO disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230322754-A1 IRAK INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-10-12 US disclosed
US-20230322799-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 UNITED STATES GOVERNMENT 2023-10-12 US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-11739087-B2 Inhibiting (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-08-29 US disclosed
WO-2023147312-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-10342811-B2 Methods of inhibition of protein fucosylation in vivo using fucose analogs SEATTLE GENETICS, INC. (US) 2019-07-09 US disclosed
US-10308614-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-06-04 US disclosed
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-03-29 US disclosed
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-03-29 US disclosed
US-20170035790-A1 METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS SEATTLE GENETICS, INC. (US) 2017-02-09 US disclosed
US-20150076062-A1 HYDROGEL-BASED DECONTAMINATION OF AQUEOUS SAMPLES CONTAINING NANOPARTICLES Universite de Bordeaux (FR) 2015-03-19 US disclosed
US-8574907-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2013-11-05 US disclosed
US-8461328-B2 Tricyclic heterocyclic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2013-06-11 US disclosed
US-20120183997-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEATTLE GENETICS, INC. (US) 2012-07-19 US disclosed